SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

PayPal Holdings, Inc. engages in the development of technology platforms that enable digital payments and simplifies commerce experiences on behalf of merchants and consumers worldwide. Its solutions include PayPal, PayPal Credit, Braintree, Venmo, Xoom, and Paydiant products. The firm also enables consumers to exchange funds with merchants using funding sources, which include bank account, PayPal account balance, PayPal Credit account, credit, and debit card or other stored value products. It operates through United States and Other Countries geographical segments. The company was founded in December 1998 and is headquartered in San Jose, CA.

PayPal Holdings Inc

PayPal is attracting significant market attention and community speculation following reports of unsolicited takeover interest from rivals, particularly after its stock's recent slump and ahead of a leadership change. Discussion centers on potential acquisition prices and the company's perceived undervaluation.

Lucid Group, Inc. manufactures electric vehicles. It designs, develops, and builds energy storage systems for electric vehicles and supplies automakers with the battery pack system needed to power hybrid, plug-in, and electric vehicles. The company was founded in December 2007 and is headquartered in Newark, CA.

Lucid Group Inc

Lucid Group is a major talking point as its impending earnings report follows recent news of a 12% workforce reduction, fueling intense community debate over the stock's persistent new all-time lows and the company's financial outlook in the competitive EV sector.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, NEREUS, Ponvory, and HETLIOZAccess. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals is experiencing heightened trading activity following the FDA approval of its BYSANTI drug for bipolar I disorder and schizophrenia, which notably secured New Chemical Entity status and patent protection until 2044. The community is buzzing with discussions about the stock's significant undervaluation, pointing to its strengthened pipeline and past rejected buyout offers, fueling expectations for a substantial re-rating and potential M&A interest from larger pharmaceutical companies.

CrowdStrike Holdings, Inc. provides cybersecurity products and services to stop breaches. It offers cloud-delivered protection across endpoints, cloud workloads, identity and data, and threat intelligence, managed security services, IT operations management, threat hunting, Zero Trust identity protection, and log management. CrowdStrike serves customers worldwide. The company was founded by George P. Kurtz, Gregg Marston, and Dmitri Alperovitch on November 7, 2011 and is headquartered in Austin, TX.

Crowdstrike Holdings Inc - Ordinary Shares - Class A

Crowdstrike Holdings Inc

CrowdStrike is trending amid an industry-wide selloff in cybersecurity stocks, driven by investor concerns following Anthropic's new "Claude Code Security" tool. However, many in the community and analysts argue this is an overreaction, asserting that AI will enhance, not replace, the critical enterprise security solutions provided by companies like CrowdStrike.

JPMorgan Chase & Co. is a financial holding company, which engages in the provision of financial and investment banking services. It focuses on investment banking, financial services for consumers and small businesses, commercial banking, financial transaction processing, and asset management. It operates through the following segments: Consumer and Community Banking (CCB), Commercial and Investment Bank (CIB), Asset and Wealth Management (AWM), and Corporate. The CCB segment originates and services mortgage loans. The CIB segment makes markets and services clients across fixed income, foreign exchange, equities, and commodities. The AWM segment provides initial capital investments in products such as mutual funds and capital invested alongside third-party investors. The Corporate segment manages its liquidity, funding, capital, structural interest rate, and foreign exchange risks. The company was founded in 1799 and is headquartered in New York, NY.

JPMorgan Chase & Co.

JPMorgan Chase & Co

JPMorgan Chase is a major talking point due to a prominent lawsuit alleging political debanking, alongside recent regulatory fines that fuel broader community discussions around the financial sector's stability and market integrity.

BlackRock Institutional Trust Company N.A. - iShares Expanded Tech-Software Sector ETF

iShares Expanded Tech-Software Sector ETF

The iShares Expanded Tech-Software Sector ETF (IGV) is trending due to a "SaaS-pocalypse" narrative, as fears that Anthropic's Claude AI tools will disrupt enterprise software are fueling aggressive selling. The community is debating whether this downturn is an overblown panic or a fundamental shift, with many calling current valuations irrational and the sector extremely oversold amidst record volume.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending after reporting overwhelmingly positive Phase 2 clinical trial results for sonelokimab in axial spondyloarthritis, demonstrating significant efficacy and potential disease modification ahead of its Investor Day. Despite this "game-changing" data and the company's strong cash runway, the community is actively discussing market "sell the news" behavior and perceived manipulation amidst significant short interest.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TG Therapeutics is trending as the community highlights recently published long-term data confirming Briumvi's best-in-class efficacy and safety, alongside a high-profile MS awareness campaign featuring Christina Applegate. Despite these strong fundamentals and anticipated positive Q4 earnings, many express frustration over the stagnant stock price, fueling calls for a buyout to unlock shareholder value.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio (IBRX) is surging following robust Q4 earnings, a significant 700% year-over-year revenue increase, and expanding global approvals for its ANKTIVA cancer therapy in Europe and Saudi Arabia. The community is actively anticipating further catalysts and a potential short and gamma squeeze, driven by the company's groundbreaking treatments and strong financial performance.

Transocean Ltd. engages in the provision of offshore contract drilling services for oil and gas wells. It also owns and operates offshore drilling fleets such as ultra-deepwater, harsh environment, deepwater, and midwater rigs. The company was founded in 1953 and is headquartered in Steinhausen, Switzerland.

Transocean Ltd

Transocean's definitive all-stock acquisition of Valaris is establishing a dominant offshore drilling powerhouse with an expanded backlog and significant synergies, fueling community discussions about a major valuation re-rating and potential short squeeze ahead of anticipated strong Q4 earnings and an emerging multi-year industry upcycle.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Aberdeen Group plc Makes New Investment in InspireMD, Inc. $NSPR

Aberdeen Group plc bought a new stake in shares of InspireMD, Inc. (NYSE:NSPR - Free Report) in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange...

Insider Selling: InspireMD (NYSE:NSPR) Insider Sells 8,411 Shares of Stock

InspireMD, Inc. (NYSE:NSPR - Get Free Report) insider Shane Thomas Gleason sold 8,411 shares of the business's stock in a transaction that occurred on Thursday, January 22nd. The stock was sold at an...

InspireMD (NYSE:NSPR) Stock Price Down 1.8% - Should You Sell?

InspireMD (NYSE:NSPR) Trading Down 1.8% - Time to Sell...

InspireMD (NYSE:NSPR) Shares Up 2% - Should You Buy?

InspireMD (NYSE:NSPR) Trading 2% Higher - Here's Why...

InspireMD, Inc. (NSPR) Reports Q3 Loss, Tops Revenue Estimates

InspireMD (NSPR) delivered earnings and revenue surprises of 0.00% and +31.41%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Hologic (HOLX) Q4 Earnings and Revenues Beat Estimates

Hologic (HOLX) delivered earnings and revenue surprises of +2.73% and +1.49%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Intuitive Surgical, Inc. (ISRG) Q3 Earnings and Revenues Top Estimates

Intuitive Surgical (ISRG) delivered earnings and revenue surprises of +20.60% and +3.92%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

CVRx (CVRX) Surges 19.0%: Is This an Indication of Further Gains?

CVRx (CVRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

InspireMD Launches CGuard Prime Carotid Stent System in the U.S.

NSPR unveils FDA-approved CGuard Prime in the United States, targeting safer carotid procedures and stroke prevention.

Shares of InspireMD, Inc. (NSPR) dipped nearly 1% on Friday morning after it <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.inspiremd.com/en/press-center/inspiremd-reports-first-quarter-2025-financial-results/">reported</a> a wider-than-expected first quarter (Q1) loss.The company’s revenue for the quarter increased 1.2% year-on-year (YoY) to $1.52 million, above an analyst estimate of $1.45 billion, as per Finchat data.The marginal increase in revenue was driven by the continued adoption of the company’s CGuard technology in existing markets. It was offset by the impact of foreign exchange and distributors managing inventory levels in anticipation of an approval for CGuard Prime in Europe.InspireMD’s CGuard Prime carotid stent system is used to treat carotid artery disease and prevent stroke.Net loss per share came in at $0.22, compared to a net loss of $0.21 per share for the same period in 2024, but wider than an estimated loss of $0.2.The company said that it is continuing to engage with the U.S. Food and Drug Administration (FDA) regarding the application it submitted to obtain marketing approval for the CGuard Prime carotid stent system.The company also expressed optimism about approval for the system in the third quarter of 2025.CEO Marvin Slosman said that the firm’s commercial team is ready to execute at scale upon receiving FDA approval for the technology.“We continue to work interactively with the FDA and are optimistic for an anticipated approval of CGuard Prime in the third quarter of 2025. Despite dynamics within the agency and the timing of our audit in February, we are confident the remaining items will be successfully completed,” he said.On Stocktwits, retail sentiment around InspireMD stayed unmoved within the ‘bullish’ territory over the past 24 hours while message volume remained at ‘high’ levels.&nbsp; &nbsp;<figure class="image"><img style="aspect-ratio:629/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_05_09_at_11_03_25_AM_png_e35692eebb.webp" alt="NSPR's Sentiment Meter and Message Volume as of 11 a.m. ET on May 9, 2025 | Source: Stocktwits" width="629" height="62"><figcaption>NSPR's Sentiment Meter and Message Volume as of 11 a.m. ET on May 9, 2025 | Source: Stocktwits</figcaption></figure><a href="https://stocktwits.com/symbol/NSPR">NSPR stock</a> is down by about 3% this year but up by nearly 17% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/ocugen-reports-lower-than-expected-q1-loss/chiWHRQRblX">Ocugen Stock Rises On Better-Than-Feared Q1 Loss: Retail Turns Bullish</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

A candlestick chart is opened in a trading platform on a smartphone. Photo: Silas Stein/dpa (Photo by Silas Stein/picture alliance via Getty Images)

InspireMD Stock Dips On Wider-Than-Expected Q1 Loss, But Retail Is Optimistic

The company’s revenue increased marginally to $1.52 million, driven by the continued adoption of its CGuard technology in existing markets.

Equity

InspireMD, Inc. is medical device company, which engages in the development and commercialization of its proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. Its products are marketed for use mainly in patients with acute coronary syndromes, notably acute myocardial infarction and saphenous vein graft coronary interventions. The company was founded in 2005 and is headquartered in Miami, FL.

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	-$0.19	--	--	N/A
Q3 '25	-$0.19	-$0.17	12.82%	BEAT
Q2 '25	-$0.26	-$0.26	--	EXPECTED
Q1 '25	-$0.20	-$0.22	-10.00%	MISSED
Q4 '24	-$0.19	-$0.19	2.56%	BEAT

NSPR
InspireMD Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q4 '25

Historical Earnings

Latest NSPR News

NSPRInspireMD Inc